GSK's TYKERB® Receives Accelerated Approval For First-line Combination Treatment Of H
 

GlaxoSmithKline announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer...

More...